Clinical Trials | December 07, 2025
Bayer launches phase III trial testing Mirena for uterine condition with no treatments
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
EBITDA before special items decreases to €4.08 billion (7.4%)
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
Subscribe To Our Newsletter & Stay Updated
